Literature DB >> 34889437

Infectious complications and vaccines.

Per Ljungman1.   

Abstract

Infections are a major cause of morbidity and can result in mortality in long-term survivors after allogeneic hematopoietic cell transplantation. Chronic graft-versus-host disease and delayed immune reconstitution are recognized risk factors. Different strategies must be utilized depending on the individual patient's situation but include prolonged antimicrobial prophylaxis and vaccination. Some important infections due to pathogens preventable by vaccination are pneumococci, influenza, varicella-zoster virus, and SARS-CoV-2. Despite the fact that such recommendations have been in place for decades, implementation of these recommendations has been reported to be poor.
Copyright © 2021 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34889437      PMCID: PMC8791105          DOI: 10.1182/hematology.2021000294

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  36 in total

1.  Reduced immunogenicity of the adjuvanted recombinant zoster vaccine after hematopoietic cell transplant: a pilot study.

Authors:  Jose F Camargo; Rick Y Lin; Yoichiro Natori; Anthony D Anderson; Maritza C Alencar; Trent P Wang; Michele I Morris; Krishna V Komanduri
Journal:  Blood Adv       Date:  2020-10-13

2.  Immune Response Following Quadrivalent Human Papillomavirus Vaccination in Women After Hematopoietic Allogeneic Stem Cell Transplant: A Nonrandomized Clinical Trial.

Authors:  Pamela Stratton; Minoo Battiwalla; Xin Tian; Suzanne Abdelazim; Kristin Baird; A John Barrett; Caroline R Cantilena; Richard W Childs; Jessica DeJesus; Courtney Fitzhugh; Daniel Fowler; Juan Gea-Banacloche; Ronald E Gress; Dennis Hickstein; Matthew Hsieh; Sawa Ito; Troy J Kemp; Izabella Khachikyan; Melissa A Merideth; Steven Z Pavletic; Wim Quint; Mark Schiffman; Claire Scrivani; Dana Shanis; Aarthi G Shenoy; Linda Struijk; John F Tisdale; Sarah Wagner; Kirsten M Williams; Quan Yu; Lauren V Wood; Ligia A Pinto
Journal:  JAMA Oncol       Date:  2020-05-01       Impact factor: 31.777

3.  Immunogenicity and Safety of Yellow Fever Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients After Withdrawal of Immunosuppressive Therapy.

Authors:  Flore Sicre de Fontbrune; Cécile Arnaud; Morgane Cheminant; Aude Boulay; Johana Konopacki; Simona Lapusan; Christine Robin; Françoise Bernaudin; Felipe Suarez; François Simon; Gérard Socié; Nathalie Colin de Verdière; Paul-Henri Consigny
Journal:  J Infect Dis       Date:  2018-01-17       Impact factor: 5.226

4.  Poor response to hepatitis A vaccination in hematopoietic stem cell transplant recipients.

Authors:  Elen Monteiro Adati; Paula Moreira da Silva; Laura Massami Sumita; Marina de Oliveira Rodrigues; Lilian P Zanetti; Ana Cláudia F Dos Santos; Mair P de Souza; Vergilio R Colturato; Clarisse M Machado
Journal:  Transpl Infect Dis       Date:  2020-02-24       Impact factor: 2.228

5.  Adherence and immune response to revaccination following hematopoietic stem cell transplantation at a pediatric onco-hematology reference center.

Authors:  Fernanda Gouveia-Alves; Roseane Gouveia; Valéria C Ginani; Adriana Seber; Danielle A Kuramoto; Gabriel F A Murad; Fernanda G Spina; Antonio S Petrilli; Victor G Zecchin; Celso Granato; Fabianne Carlesse; Maria Isabel de Moraes-Pinto
Journal:  Transpl Infect Dis       Date:  2018-05-07       Impact factor: 2.228

6.  Severe Herpes Zoster Requiring Intravenous Antiviral Treatment in Allogeneic Hematopoietic Cell Transplantation Recipients on Standard Acyclovir Prophylaxis.

Authors:  Emily Baumrin; Matthew P Cheng; Sanjat Kanjilal; Vincent T Ho; Nicolas C Issa; Lindsey R Baden
Journal:  Biol Blood Marrow Transplant       Date:  2019-04-17       Impact factor: 5.742

7.  Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution.

Authors:  Fulvia Pimpinelli; Francesco Marchesi; Giulia Piaggio; Diana Giannarelli; Elena Papa; Paolo Falcucci; Martina Pontone; Simona Di Martino; Valentina Laquintana; Antonia La Malfa; Enea Gino Di Domenico; Ornella Di Bella; Gianluca Falzone; Fabrizio Ensoli; Branka Vujovic; Aldo Morrone; Gennaro Ciliberto; Andrea Mengarelli
Journal:  J Hematol Oncol       Date:  2021-05-17       Impact factor: 17.388

8.  Ibrutinib for steroid refractory chronic graft-versus-host disease: therapeutic efficiency can be limited by increased risk of fungal infection.

Authors:  Panayotis Kaloyannidis; Ahmed Ayyad; Zakaria Bahaliwah; Belal Blowi; Wael Alanazi; Zahra Al Shammasi; Hamdi Elsoudi; Ibrahim Ibrahim; Hani Al Hashmi
Journal:  Bone Marrow Transplant       Date:  2021-05-04       Impact factor: 5.174

9.  Humoral immune response to tick-borne encephalitis vaccination in allogeneic blood and marrow graft recipients.

Authors:  Nicole Harrison; Katharina Grabmeier-Pfistershammer; Alexandra Graf; Ilse Schwarzinger; Judith H Aberle; Karin Stiasny; Hildegard Greinix; Werner Rabitsch; Peter Kalhs; Michael Ramharter; Heinz Burgmann; Christina Forstner
Journal:  NPJ Vaccines       Date:  2020-07-24       Impact factor: 7.344

10.  Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.

Authors:  Yair Herishanu; Irit Avivi; Anat Aharon; Gabi Shefer; Shai Levi; Yotam Bronstein; Miguel Morales; Tomer Ziv; Yamit Shorer Arbel; Lydia Scarfò; Erel Joffe; Chava Perry; Paolo Ghia
Journal:  Blood       Date:  2021-06-10       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.